Gadodiamide

Gadodiamide is a gadolinium-based MRI contrast agent, used in MR imaging procedures to assist in the visualization of blood vessels.

Product information

CAS Number: 131410-48-5

Molecular Weight: 573.66

Formula: C16H26GdN5O8

Synonym:

DV 7572

DV-7572

DV7572

Omniscan

S 041

S-041

S041

Chemical Name: Gadolinium, [5, 8-bis(carboxymethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2, 5, 8, 11-tetraazatridecan-13-oato(3-)]-

Smiles: [Gd+3].CNC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC(=O)NC

InChiKey: HZHFFEYYPYZMNU-UHFFFAOYSA-K

InChi: InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: Solubility (25°C) DMSO: Insoluble. Water: 100 mg/mL(169.01 mM).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Gadodiamide results in half-life of 18, 38, and 75 minutes in rats, rabbits, and monkeys, respectively. Gadodiamide is shown to be excreted rapidly, primarily through the kidneys. Gadodiamide, when administered i.v. as gadodiamide injection at a dosage of 0.3 mmol/kg, is stable in vivo and that the very major part of the dose (> 99%) is excreted in urine as an unchanged complex. Gadodiamide produces focal and generalized myoclonus over several hours. Gadodiamide itself produces lesions in the central cerebellar regions resembling in character and severity those produced by the gadodiamide formulation, but not others. Gadodiamide travels quickly throughout the ventricular system from the lateral ventricular site of injection to the fourth ventricle and foramina of Luschka and Magendie within 2 min. Gadodiamide results in transient but statistically significant decreases in aortic pressure, left ventricular pressure, indices of left ventricular contractility and relaxation, and systemic and pulmonary vascular resistance, and increases in aortic blood flow in anesthetized dogs. Gadodiamide injection produces less severe alterations in hemodynamics than gadopentetate dimeglumine.

References:

1. Ray DE, et al. AJNR Am J Neuroradiol, 1998, 19(8), 1455-1462.
2. Normann PT, et al. Eur J Drug Metab Pharmacokinet, 1995, 20(4), 307-313.
3. Harpur ES, et al. Invest Radiol, 1993, 28, S28-43.

Products are for research use only. Not for human use.